radiotherapy
-
Tislelizumab regimen reached 45.3% pathological complete response in rectal cancer
In this 118-patient randomised phase II trial, adding tislelizumab to short-course radiotherapy and CAPOX chemotherapy was associated with a higher pathological complete response rate than the same treatment…